<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Brentuximab vedotin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB08870</strong></td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Brentuximag vedotin or Adcetris&#174; is an antibody-drug conjugate that combines an anti-CD30 antibody and the drug monomethyl auristatin E (<span class="caps">MMAE</span>). It is an anti-neoplastic agent used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Brentuximag vedotin was approved in 2011, and in January 2012, the drug label was revised to include a boxed warning of progressive multifocal leukoencephalopathy and death following JC virus infection.</p></td></tr><tr><th>Protein structure</th><td><img alt="No structure small" src="/assets/no_structure_small-e8790a148b09ecc5ad9f5b4926a538e7.png"></td></tr><tr><th>Protein chemical formula</th><td>C<sub>6476</sub>H<sub>9930</sub>N<sub>1690</sub>O<sub>2030</sub>S<sub>40</sub></td></tr><tr><th>Protein average weight</th><td>149.2&#8211;151.8 kDa</td></tr><tr><th>Sequences</th><td></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>cAC10-vcMMAE</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Adcetris</td><td>Seattle Genetics</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>914088-09-8</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Superclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Class</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.</td></tr><tr><th>Pharmacodynamics</th><td>Brentuximag vedotin causes apoptosis of tumor cells by preventing cell cycle progression of the G2 to M phase through disruption of the cytosolic mictrotuble network.</td></tr><tr><th>Mechanism of action</th><td>Brentuximab vedotin is composed of 3 parts: a chimeric human-murine IgG1 that targets CD30, monomethyl auristatin E (MMAE),which is a microtubule disrupting agent, and a protease-susceptible linker that covalently links the antibody and MMAE. The IgG1 antibody enables brentuximab vedotin to target tumor cells expressing CD30 on their cell surface then brentuximab vedotin gets internalized into the cell. Once inside, the linker is cleaved releasing MMAE which binds disrupts the microtuble network. </td></tr><tr><th>Absorption</th><td>Brentuximab vedotin is administered only as an intravenous infusion so absorption is 100%.</td></tr><tr><th>Volume of distribution</th><td><p>The steady state volume of distribution is 6-10 L.</p></td></tr><tr><th>Protein binding</th><td>MMAE has a plasma protein binding range of 68-82%, and highly-protein bound drugs are not likely to displace it.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Only a small fraction of MMAE is metabolized primarily via oxidation by CYP3A4 and CYP3A5.</p></td></tr><tr><th>Route of elimination</th><td>MMAE is eliminated by the feces (with 72% unchanged) and urine.</td></tr><tr><th>Half life</th><td>The terminal half-life is 4-6 days. </td></tr><tr><th>Clearance</th><td><p><span class="caps">MMAE</span> is cleared by the liver but not quantitative studies have been performed.</p></td></tr><tr><th>Toxicity</th><td>The most severe toxic reaction seen in patients is progressive multifocal leukoencephalopathy. Other toxicities include bone marrow suppression, infusion reactions, peripheral neuropathy, Stevens-Johnson syndrome, and tumor lysis syndrome.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, powder, for solution</td><td>Intravenous</td><td>1.8 mg/kg (maximum dose: 180 mg) every 3 weeks</td></tr></tbody></table></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00290">Bleomycin</a></td><td>Pulmonary toxicity of bleomycin may be increased. Avoid combination.</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Brentuximab, when used concomitantly with etravirine, may experience a decrease in serum concentrations. The levels of an active metabolite of brentuximab, monomethyl auristatin E, may decrease. It is recommended to monitor efficacy of brentuximab therapy. </td></tr><tr><td><a href="/drugs/DB00108">Natalizumab</a></td><td>Avoid combination due to the increased risk of concurrent infection.</td></tr><tr><td><a href="/drugs/DB00337">Pimecrolimus</a></td><td>Avoid combination due to the potential enhancement of toxic effects of immunosuppressants</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Avoid combination due to the potential enhancement of toxic effects of immunosuppressants.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>